Dr. Domenica Lorusso on Pembrolizumab + Chemoradiation for Advanced Cervical Cancer

8 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published May 21, 2025

In this session at ESTRO 2025, Dr. Domenica Lorusso, Full Professor at Humanitas University, Rozzano, Italy, and Director of the Operative Unit of Gynecological Oncology at Humanitas San Pio X, presents the KEYNOTE-A18 trial results. The trial is the first to evaluate the combination of Pembrolizumab (an anti-PD-1 inhibitor) with chemoradiation in the treatment of locally advanced high-risk cervical cancer.

Key Findings:
✅ 30% reduction in the risk of disease progression
✅ 33% reduction in the risk of death
✅ No increase in toxicity despite the addition of Pembrolizumab
✅ Manageable immune-related side effects (mainly thyroid dysfunction)
✅ Quality of life unaffected by treatment

Dr. Lorusso discusses the significance of this additive synergy between radiotherapy and immunotherapy, explaining how modern radiotherapy has reduced toxicity, making this combination approach highly promising for advanced cervical cancer treatment.

About ESTRO 2025

ESTRO 2025 is the leading global event for radiation oncology professionals, hosted by the European Society for Radiotherapy and Oncology (ESTRO). This congress, held from May 2 to 6, 2025, at the Messe Wien Exhibition & Congress Center in Vienna, Austria, brings together experts from around the world to showcase cutting-edge research, discuss the latest advancements in radiotherapy, and explore future trends in oncology.

#ESTRO2025 #CervicalCancer #Pembrolizumab #Chemoradiation #Immunotherapy #OncologyResearch #GYNOncology #CervicalCancerTreatment #CancerImmunotherapy #Radiotherapy #CancerResearch

SUBSCRIBE to get the latest #oncodaily https://www.youtube.com/@OncoDailyTV

Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn: https://linkedin.com/company/oncodaily
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram: https://www.instagram.com/oncodailynews/
Follow OncoDaily on TikTok: https://www.tiktok.com/@oncodaily
Like OncoDaily on Facebook: https://www.facebook.com/oncodaily/

SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter

About OncoDaily
OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”